BBIO
HEALTHCAREBridgeBio Pharma Inc
$68.09-0.69 (-1.00%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BBIO Today?
No stock-specific AI insight has been generated for BBIO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$31.77$84.94
$68.09
Fundamentals
Market Cap$13.2B
P/E Ratio—
EPS$-3.78
Dividend Yield—
Dividend / Share—
ROE-17.9%
Profit Margin-1.4%
Debt / Equity—
Trading
Volume2.6M
Avg Volume (10D)—
Shares Outstanding193.9M
BBIO News
22 articles- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 8, 2026
- BridgeBio (BBIO) Q1 2026 Earnings TranscriptMotley Fool·May 8, 2026
- BridgeBio Pharma Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- BridgeBio Pharma Announces $500 Million Stock Repurchase ProgramTipRanks·May 7, 2026
- BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 7, 2026
- BridgeBio Reports First Quarter 2026 Financial Results and Corporate UpdatesYahoo Finance·May 7, 2026
- A Look At BridgeBio Pharma (BBIO) Valuation After Recent Trading Weakness And Pipeline ExpectationsYahoo Finance·May 6, 2026
- BridgeBio to Participate in May and June Investor ConferencesYahoo Finance·May 6, 2026
- BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in BrazilYahoo Finance·May 6, 2026
- BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECEYahoo Finance·May 5, 2026
- BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026Yahoo Finance·May 4, 2026
- BridgeBio Pharma Inc. (BBIO): Billionaire Tom Steyer Admires Upside Potential of This StockYahoo Finance·May 2, 2026
- Alnylam Surges After Its Pfizer-Rivaling Blockbuster Jumps Nearly 200%Yahoo Finance·Apr 30, 2026
- BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ETYahoo Finance·Apr 30, 2026
- Is Attruby’s Accelerating Launch and Star-Studded Awareness Campaign Altering The Investment Case For BridgeBio Pharma (BBIO)?Yahoo Finance·Apr 30, 2026
- Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?Yahoo Finance·Apr 29, 2026
- BridgeBio (BBIO) Q2 2025 Earnings TranscriptMotley Fool·Apr 28, 2026
- Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should KnowYahoo Finance·Apr 28, 2026
- BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. WhiteYahoo Finance·Apr 28, 2026
- Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.Biopharmadive·Apr 28, 2026
- Is It Too Late To Consider BridgeBio Pharma (BBIO) After Its 101.8% One-Year Surge?Yahoo Finance·Apr 25, 2026
- Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54GlobeNewswire Inc.·Mar 30, 2026
All 22 articles loaded
Price Data
Open$69.81
Previous Close$68.78
Day High$70.42
Day Low$67.48
52 Week High$84.94
52 Week Low$31.77
52-Week Range
$31.77$84.94
$68.09
Fundamentals
Market Cap$13.2B
P/E Ratio—
EPS$-3.78
Dividend Yield—
Dividend / Share—
ROE-17.9%
Profit Margin-1.4%
Debt / Equity—
Trading
Volume2.6M
Avg Volume (10D)—
Shares Outstanding193.9M
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—